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BOTANICAL DRUGS: A FUTURE FOR
HERBAL MEDICINES
Weishi Li*
INTRODUCTION
In recent years, herbal medicines have attracted strong attention in the
United States and worldwide, as part of a larger fascination with natural
products. This paper explores the future of herbal medicines in the
United States and makes the case that botanical drugs, as a new drug
model for herbal medicines, will lend a much-needed arsenal to the
perennial fight against human diseases.
The current regulatory state of affairs regarding herbal medicines is
sub-optimal as it fails to spur rigorous efforts to research and develop
effective drugs from herbal medicines. Due to an unfavorable regulatory
climate, few U.S. companies engage in developing drug products from
herbal medicines. It is argued here that the Food and Drug
Administration (FDA) should promote industrial efforts in exploring
herbal medicines by approving botanical drugs using a substantially lower
regulatory standard. Such a policy will benefit both consumers and a
pharmaceutical industry suffering a "dry spell" in conventional drug
development.
The first section of this paper illustrates the huge market potential for
herbal medicines within the United States, and globally. It points out that
this market potential could be curtailed by the lack of standardization and
scientific validation for many herbal medicines. The second section
examines the crisis facing the American pharmaceutical industry and the
limitation of the conventional "silver bullet" approach to drug
development. The third section contends that developing botanical drugs
from herbal medicines can bring the better of the two worlds together. It
promises to alleviate the "dry spell" facing the pharmaceutical industry,
and bring more effective medicines to patients at a faster rate. The fourth
section examines the current regulatory climate and points to the
disincentive effect of the current regulations. Rationales for adopting a
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lower standard for botanical drug approval are discussed. The last section
assesses the Draft Guidance for Botanical Drug Products (Draft
Guidance), released by FDA in August 2000 for incentives to industry
efforts in developing herbal medicines. Finally, this paper proposes
further changes to be adopted in the final Guidance.
I. THE MARKET: THE UNITED STATES AND WORLDWIDE
The projected worldwide market size for herbal medicine is staggering.
One study, in 1987, estimated the global market at about eighteen to
twenty billion dollars U.S.' Asia dominates as the largest market at about
forty percent of the share; Europe follows at thirty-five percent, and North
America accounts for about seventeen percent.2
The U.S. market is equally promising. Partially fueled by the passage of
the Dietary Supplement Health and Education Act (DSHEA), the U.S.
market saw a rise in the sales of herbal products, in the form of dietary
supplements, from $3.3 billion to $6.5 billion between 1990 and 1996.3 The
rise in the sale of these products can be directly attributed to the
increasing number of people using herbs. Within seven years, from 1991
to 1998, the percentage of the American population using herbs increased
from a mere four percent to a significant thirty to thirty-five percent in
1998.4
Despite the tremendous growth, the U.S. market still has plenty of
room to grow. The percentage of American consumers using herbal
products remains low compared to many other nations. While Americans
were slow to adopt the worldwide trend of consuming herbal products,
other nations' consumption patterns may shed light on the current
direction of the U.S. market. For instance, over sixty percent of the
population in Germany, and eighty to ninety percent of the population in
China, use herbs regularly By inference, the U.S. market is still capable
of expanding to reach another thirty to forty percent of the population,
1. See Peggy Brevoort, Global Market for Botanical Products, in DRUG
DISCOVERY AND TRADITIONAL CHINESE MEDICINE 157, 161 (2001).
2- Id.
3. See PAULA KURTZWEIL, FOOD AND DRUG ADMINISTRATION, U.S.
DEPARTMENT OF HEALTH AND HUMAN SERVICES, A FDA GUIDE TO DIETARY
SUPPLEMENTS, 1998-1999, available at http://www.fda.gov/fdac/features/
1998/598_guid.html.
4. See Brevoort, supra note 1, at 160.
5. Id.
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making the U.S. an enticing market given the consumption power of
Americans.
The real picture, however, may be more complicated. Many factors,
including cultural, traditional and infra-structural ones, contribute to
consumers' purchase choices in medicines. For example, China's use of
plant-derived remedies to treat diseases is a part of its national cultural
heritage. The practice of traditional Chinese medicine dates back as early
as 2800 B.C., as documented in the "Herbal Classic of the Divine
Plowman" (Sheng Nung Ben Cao Chien).' As an indication of the
prevalence of traditional Chinese medicine (TCM), China now boasts
more than 2500 TCM hospitals and thirty universities and colleges
engaging in the studies of TCM.7 The Chinese government, consumers
and medical professionals hold TCM and western medical science at equal
status. Given the tradition and the supportive infrastructures in place, it is
not surprising that eighty to ninety percent of the Chinese population use
herbal medicines on a regular basis."
Conversely, the U.S. is a study in stark contrast. The faith in FDA-
approved prescription drug and over-the-counter (OTC) drugs is deeply
ingrained in American consumers. On the one hand, the medical
profession, conservative by training, is understandably reluctant to
embrace herbal medicine. On the other hand, the practice of traditional
herbal medicine remains largely confined to Chinese enclaves in large
coastal cities within the U.S. As a result, while many consumers recognize
the merits of herbal medicine, the American medical mainstream remains
ambivalent to their efficacy. Such ambivalence makes further expansion of
the herbal medicine market in the U.S. a questionable prospect.
The growth trend of the U.S. dietary supplement market to date seems
to validate this concern. After witnessing astonishing growth from 1994 to
1997, the American market for dietary supplements leveled off in 1998 and
demand may currently be in decline.9 This stalled growth is fueled partly
by a hostile press, hot on the pursuit of fraudulent manufacturers, and
partly by the long-held western perception that these herbal medicines are
6. See Stringner Yang, et al., The Camptothecin Experience: From Chinese
Medicinal Plants to Potent Anti-Cancer Drugs, in DRUG DISCOVERY AND
TRADITIONAL CHINESE MEDICINE 62 (2001).
7. Yongzheng Hui, Approaching Traditional Chinese Medicine: Inheritance
and Exploration, in DRUG DISCOVERY AND TRADITIONAL CHINESE MEDICINE 2
(2001).
8. Id.
9. See Michael Chang, Opportunities and Challenges of Developing Medicinal
Herbs, in DRUG DISCOVERY AND TRADITIONAL CHINESE MEDICINE 169 (2001).
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in the league of quackery. This plateau in sales growth highlights the
concern about the sustainability of herbal medicines, in their traditional
form, in the U.S. market.
Botanical drugs, developed from herbal medicines, can potentially
overcome the consumer suspicions and fulfill the promise of herbal
medicines. A clarification of terminology is necessary. A botanical drug,
as defined by the FDA in its Draft Guidance, is a botanical product
prepared from a botanical drug substance, and intended for use as a drug.'0
A conventional FDA-approved drug has a single well-characterized active
ingredient. By contrast, a botanical drug, by definition, comes in forms of
extracts that are composed of multiple chemical constituents.' The
concept of botanical drugs places herbal medicine into the vigorous FDA
drug approval process. As a result, the development of botanical drugs
will demand the combination of the merits of advanced western
technology and the empirical-based, centuries-old herbal medicine
tradition.
The development of botanical drugs, given the right regulatory climate,
will allow American pharmaceutical companies to capitalize on the
existing market for herbal medicines both here and abroad, and allow
them to reach those consumers traditionally suspicious of herbal
medicines.
II. CRISIS IN CONVENTIONAL DRUG DISCOVERY
The American pharmaceutical industry is currently in the midst of a
productivity crisis. To better understand the plight of pharmaceutical
companies, it is necessary to briefly summarize the drug approval process
for a new chemical entity (NCE) drug.
A. Conventional FDA Drug Approval Process
Before starting human clinical trials in the U.S., a company must file an
investigational new drug (IND) application with FDA. The FDA then has
thirty days to intervene. 2 If FDA fails to intervene within that period, the
company may proceed with testing. 3 The tests are customarily divided
10. See U.S. FOOD AND DRUG ADMINISTRATION: GUIDANCE FOR INDUSTRY,
at 36 (August 2000), available at www.fda.gov/cder/guidance/1221dft.pdf
[hereinafter BOTANICAL DRUG GUIDANCE].
11. Id.
12. See Peter Barton Hutt & Richard A. Merrill, FOOD AND DRUG LAW: CASES
AND MATERIALS 516 (2d ed.1991).
13. Id.
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into three phases. In a Phase I clinical trial, companies test for safety on
twenty to eighty healthy volunteers. 4 Before administrating the drug to
volunteers, companies need to supply preclinical data, including
pharmacological and toxicological data, which are subject to review by
clinical pharmacologists.'5 If the data are deemed satisfactory, the drug is
then administrated to the volunteers.' 6 In Phase II, companies test for
efficacy of the drug in 100-300 patients under different dosages. 7 Phase
III calls for extensive trials on hundreds or even thousands of patients.
Usually at least two adequate and well-controlled Phase III studies are
required." The objective is to establish proof of efficacy and acceptable
side effects. If the drug remains promising after all three phases, the
company submits clinical, pharmacological and toxicological data in the
form of a new drug application (NDA) to FDA. 0 Currently, it takes FDA
on average a year to review an NDA.2' Only upon the approval of an
NDA by FDA can a company proceed to market its drug.
The entire drug development process is long and costly. Bringing a
single new chemical entity (NCE) drug to market now takes ten to fifteen
years on average and costs over $800 million, a sum exceeding the gross
national product of some nations.2 Moreover, this cost is steadily rising at
the rate of eleven percent annually.23
A significant portion of the cost comes from candidate attrition
during the clinical stage of drug development and the FDA approval
process.24 "[F]or every five to six drug candidates that reach
14. Id.
15. Id.
16. Id.
17. Id.
l& Id.
19. Id.
20. Id.
21. See U.S. FOOD AND DRUG ADMINISTRATION, FDA's DRUG REVIEW AND
APPROVAL TIMES (July 30, 2001), at http://www.fda.govlcder/reports/reviewtimes
/default.htm.
22. See Joseph Chang, Medicinal Herbs: Drugs or Dietary Supplement? 59
BIOCHEMICAL PHARMACOLOGY 211, 211 (2000).
23. See Jeffrey S. Handen, The Industralization of Drug Discovery, at
http://www.drugdiscoverytoday.com.
24. See Jasjit S. Bindra et al., Back to Nature: The Alternative Paradigm for
Drug Development, in DISCOVERY AND TRADITIONAL CHINESE MEDICINE 152
(2001).
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Investigational New Drug (IND) status, only one becomes a product."
To illustrate, pharmaceutical companies will typically market roughly one
out of a hundred of their patented products.26 The skyrocketing research
and development (R&D) costs have translated directly into soaring prices
for prescription drugs. As a Wall Street Journal article observed, drugs
"commonly [cost] no more than $2 a pill a few years ago. The new-
generation drugs cost $4, $11, even $15 per pill.
2 7
B. Drying Drug Pipelines
The American pharmaceutical industry is in the midst of a productivity
crisis. Jean-Pierre Garnier, the Chief Executive Officer of
GlaxoSmithKline, recently lamented that "[w]e don't have enough in our
collective pipelines. 2 8 This is not a problem for an isolated few, but one
that plagues the entire pharmaceutical industry. In 2000, the Wall Street
Journal reported that since 1996, the production of breakthrough drugs
has steadily declined.29 In 1996, there were fifty-three new FDA-approved
drugs.30 This decreased in 1999 to only thirty-five, and to just sixteen in
the first half of 2000.3' Kenneth Kaitin, director of the Tufts Center for the
Study of Drug Development, summed it up: "these [pharmaceutical] firms
will need to put out at least three or four new chemical entities per year
[to sustain growth rates] and there's no firm right now doing anything
more than one per year. It is a very tenuous time for the pharmaceutical
industry.
3 2
Recent news confirms that trouble continues for the largest
pharmaceutical companies. Merck, Bristol-Myers Squibb, Schering-
Plough and Eli Lilly have all recently issued earnings warnings to Wall
Street33 due to patent expiration of major drugs and a lack of new drugs. 4
25. Id.
26. See Michael R. Ward, Drug Approval Overregulation, 15 CATO
REGULATION 4, (1992), available at www.cato.org/pubs/regulation/regl5n4e.html.
27. See Elyse Tanouye: Hard to Swallow, America's Soaring Drug Costs, WALL
ST. J., Nov. 16, 1998, at A10.
28. See Gardiner Harris, New Script: Drug Firms, Stymied in the Lab, Become
Marketing Machines, WALL ST. J., July 6, 2000, at Al.
29. Id. at A12.
30. Id.
31. Id.
32 Id.
33. See Gardiner Harris, Back to the Lab: Merck to Shed Medco, Its Drug-
Benefits Units, In Bid to Boost Stock, WALL ST. J., January 29, 2002, at Al.
34. Id.
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With no new drugs on the horizon, the prospect of a recovery in
productivity is slim.
Worse than the decline in productivity is how pharmaceutical
companies responded. Rather than increasing research, "the
pharmaceutical industry is gradually shifting the core of its businesses
away from the unpredictable and increasingly expensive task of creating
drugs and toward the steadier business of marketing them."3 While this
strategy is a short-term response to boost a company's bottom line, it is
not a long-term solution to the productivity problem. Ultimately, patients
will suffer, and society will pay increased medical expenses.
C. Lost faith in "Silver Bullets"
The current crisis in new drug discovery highlights the limitation of the
conventional view of drugs as "silver bullets." The traditional belief that a
single chemical entity drug, which treats a single disease, rests on a critical
premise that human diseases have a uniform, underlying genetic basis
across patient populations. Typically, a silver bullet drug is a NCE drug
with a single active chemical ingredient. While there have been
blockbuster silver bullets like Amgen's EPO and Eli Lilly's Prozac, the
hope for new blockbuster drugs has diminished.36 Recent advances in
genomics vindicate this pessimism. It appears that diverse genetic changes
often underlie a single disease, a phenomenon termed "polymorphism."
Thus, different patient populations may require different drugs tailored to
their personal needs. The polymorphic nature of diseases suggests an
individualized approach in drug design is more likely to succeed, making it
even more difficult to develop blockbuster drugs.37
In sum, the American pharmaceutical industry is in a "terrible trough. 38
There is a dire need to find a complementary way to supplant the current
approach toward drug discovery. Some pin their hopes on the advent of
genomics and the complete sequences of the human genome. While
genomic knowledge will undoubtedly offer new insight into human
35. Id. at Al.
36. See Harris, supra note 28, at 30 (quoting Fred Hassan, chairman of
Pharmacia Corp, as saying "we are well past the low-hanging fruit. It's becoming
very difficult to get easy wins.").
37. Indeed, Millennium, the next generation genomic pharmaceutical
company, prides itself in its promise of delivering "personalized medicine". See
http://www.millennium.com/about/index.asp and http://www.millennium.com/
about/personalized/index.asp (last visited Feb. 8, 2003)
38. Harris, supra note 33.
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diseases, most genomic experts speculate that significant drug discoveries
based on genomics are still years away. 9 Given the heightened interest in
herbal medicines in the United States and worldwide, the development of
botanical drugs may be the booster shot that the pharmaceutical industry
badly needs.
III. BOTANICAL DRUGS: A MARRIAGE BETWEEN HERBAL
MEDICINES AND WESTERN DRUG DEVELOPMENT
A. What Herbal Medicines Offer
Herbal medicines offer hope to alleviate the current crisis in
conventional drug development. It is important to stress that herbal
medicines will not replace conventional drugs. Rather, they will
complement conventional drug discovery. There are at least three reasons
why herbal medicines may offer the perfect complement to conventional
drug discovery.
First, capitalizing on knowledge of herbal medicines may give rise to
cheaper and faster ways of drug discovery. Typically, drug discovery starts
with screening millions of chemicals against biological targets using cell-
based assays in laboratories.'o Promising chemicals (leads) are then tested
in animal disease models.4' Candidates that survive the animal testing
then move on to expensive clinical trials.42 As previously mentioned, only
a small percentage of these candidates survive the ordeal of clinical trials
to become a product. This is often due to unforeseen side effects or lack of
efficacy in human subjects.43  The lack of a correlation between
pharmacological activity against targets and clinical effectiveness is the
principal culprit for the high attrition rate at later clinical stages." The
problem lies in the risky practice of using laboratory screening and animal
disease models to predict therapeutic efficacy in humans. The lab
screening and animal models often carry "inadequate predictive power" as
to a product's effectiveness in human patients.5
Capitalizing on knowledge of herbal medicines may lead to a way out of
this costly dilemma. Botanical extracts can be directly evaluated for
39. Id.
40. See HuTr & MERRILL, supra note 12, at 514.
41. Id.
42 Id.
43. Id.
44. Id.
45. See Bindra, supra note 24, at 152.
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clinical efficacy, rather than subjected to initial chemical isolation. This
releases drug discovery from absolute reliance on laboratory screens and
enables the development of drugs for poorly understood diseases that lack
laboratory screening methods and animal models. These products can
then be developed either as botanical drugs - standardized, heterogeneous
mixtures or as purified single-chemical entity drugs.
Naturaceuticals, a new drug development paradigm championed by
Pfizer, seeks to accomplish this end.46 At an international conference on
traditional Chinese medicine, Pfizer's representative described this new
paradigm:
The development paradigm for naturalceuticals differs from the
established pharmaceutical strategy in that it seeks up front to
rapidly address clinical efficacy with candidates having anecdotal
or folklore histories of use in humans, before investing in costly,
time-consuming R&D work. . Opportunities with proven
clinical efficacy may then become fully invested for the costly
process. . . While this approach appears to turn conventional
R&D on its head, it only acknowledges the way drugs were
discovered once upon a time. 7
Indeed, developing drugs from plants is not new to American
pharmaceutical companies. Taxol, aspirin, menthol and morphine, are
examples of single-ingredient drugs derived from plants. However, taking
advantage of the traditional knowledge in herbal medicines to give the
drug development process a head start is a new concept for these
companies.
Second, herbal medicines offer a holistic approach to complement a
pure reductionism approach toward diseases, namely, the silver bullet
approach. The drug industry often prides itself on the scientific and
reductionist approach toward drug development. History, however,
shows that many blockbuster drugs came not necessarily as a result of
impeccable R&D, but by way of inadvertent good fortune. For example,
the initial discovery of Viagra came from a surprising side effect in clinical
trials designed for heart conditions.'* Thus, merits of the reductionism
46. Id. at 154.
47. Id.
48. Pfizer researchers who gave out Viagra in clinical trials were puzzled by
the reluctance of patients to give back the supposedly "ineffective" drug. It took
some further digging to uncover the value of the now blockbuster wonder drug.
See Paul Witte, Viagra: History in the Makingor Products Liability History
Repeating Itself? at http://pegasus.rutgers.edu/-record/drafts/viagra.html (last
visited Feb. 8, 2003)
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approach may be greatly exaggerated to the exclusion of other useful
approaches.
In contrast to the silver bullet approach, herbal medicines often
integrate preventive and curative measures. For example, traditional
Chinese medicine recipes typically contain multiple herbs.4 9 While one
herb alleviates disease directly, the others may work by promoting general
well being of the body to boost its defense abilities. Such a strategy indeed
makes sense in view of the modern knowledge of how the immune system
works. Modern medicine informs us that, by boosting our immune
systems, we can help our bodies to better fight diseases.
Tied to the holistic approach is the third advantage of herbal medicines,
namely, synergism among different components. While the mechanism of
most herbal medicines remains elusive, it appears that synergy among
different elements can be an important part of their overall medicinal
effects.50 Indeed, laboratory studies have demonstrated the existence of
such synergy at the molecular level in some traditional Chinese
medicines." Such synergistic action may confer a unique advantage,
especially in dealing with complex diseases of polymorphic nature that are
unresponsive to the conventional single chemical entity drugs. To this
end, many traditional formulas have exhibited activity against asthma,
metabolic diseases, pain, depression and infectious diseases including
AIDS and cancer. 2 The claims for treating cancer have been supported by
findings at the National Institutes of Health (NIH). Researchers at the
National Products Branch at NIH reported that camptothecin (CPT),
isolated from extracts prepared from the barks of a Chinese medicinal
tree, showed broad-spectrum anti-tumor activity. 3 In fact, Pharmacia
Upjohn is producing and marketing a CPT analog, CPT-11, under the
trade name of camptosar or irnnotecan4 Additionally, there are over 130
clinical trials involving different versions of CPT analogs, for treating
49. See Benson, et al., Antibacterial Synergy in Rubricine: An Extract from the
Roots of Arnebia Euchroma, A Chinese Medicinal Herb, in DISCOVERY AND
TRADITIONAL CHINESE MEDICINE 111 (2001).
50. Id. at 112.
51. For example, researchers from the University of Maryland reported that an
extract from the roots of a Chinese medicinal herb was found to have antibacterial
synergy. Id.
52 See Yang, supra note 6, at 63.
53. Id. at 63.
54. Id. at 71.
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diverse cancers, at early and late stages, and in cases where there are
multiple cancers."
B. Validity of Herbal Medicines: Traditional Chinese Medicine as a
Case in Study
Advocating for botanical drugs based on knowledge of herbal
medicines necessarily raises the question: are the underlying herbal
medicine claims valid? As herbal medicines encompass a formidable
range of medicines from vastly different sources, this section examines
only the validity of TCM. However, it is important to stress that the
regulatory issues discussed in this paper should be generally applicable to
any herbal medicines that are comparably supported by empirical data, as
with TCM.
The prevalence of TCM in China and other Asian countries suggests its
effectiveness. In China, where western drugs are widely available and
relatively affordable in major cities,5 6 a recent survey reveals that the
majority of consumers view TCM as equally or more effective than
western drugs. This perception is not surprising. The long history of
trial-and-error practice and documentation have accumulated a wealth of
empirical knowledge and clinical data regarding the effects of herbs on
diseases and their associated side effects.
While prevalence builds a circumstantial case for the validity of TCM
claims, pharmacological and/or clinical studies performed in the west
provide direct evidence. A weighty piece of evidence came from a recent
controversy involving Merck, a pharmaceutical powerhouse, and
Pharmanex, a California-based dietary supplement manufacturer. In this
case, Cholestin, a dietary supplement based on traditional Chinese
medicine knowledge, turned out to contain the same active ingredient as
Mevacor, Merck's FDA-approved prescription drug. 8 Red yeast rice,
traditionally prepared by fermenting non-glutinous rice with red yeast, has
55. Id.
56. The availability and affordability of western drugs is in large part due to
the prevalence of "me too" drugs, a phenomena likely to end soon as China
recently joined WTO. "Me too" drugs are cheap domestically-produced versions
of western drugs.
57. See Hui, supra note 7, at 2. (The survey conducted among 1543 households
in Beijing, Shanghai and Guangzhou showed that forty-one percent believe that
TCM and western medicine are equally effective, thirty-one percent prefer TCM
to western drugs and only twenty-three percent prefer western drugs). Id.
58. Pharmanex v. Shalala, 221 F.3d 1151 (10th Cir. 2000).
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long been known for its cholesterol-lowering ability." Indeed, the
classical book on TCM, Ben Cao Gang Mu (Compendium of Materia
Medica, 1578 A.D.) describes the ability of TCM to "invigorate spleen,
digestion, and promote blood circulation and resolve blood stasis. '
Pharmanex developed a red yeast rice extract and marketed it under the
name Cholestin.6 ' Cholestin contains a natural substance, mevinolin,
which is chemically identical to the active ingredient, lovastatin, in the
prescription drug Mevacor.62  Mevacor was developed and marketed by
Merck for the treatment of high cholesterol and heart disease. 63 This
illustrates that ancient empirical-based traditional Chinese medicine
knowledge and costly state-of-the-art western pharmaceutical research can
converge.
The validity of TCM is not limited to this single instance. Laboratory
studies validating TCM claims are abundant in scientific literature. 
6
Clinical trials of products based on the knowledge of TCM, in both the
United States and Europe, lend further support to its validity.65 In the
United States, for example, clinical trials funded by NIH - some now in
Phase III - suggest that ginkgo extract may be effective for Alzheimer's
disease, that chondroitin sulfate may affect osteoarthritis, and that saw-
palmetto extract might ameliorate benign prostrate hypertrophy. 6
C The Flip Side: What Western Drug Development Processes Offer
Herbal Medicine
Herbal medicines offer hope for drug development; however, herbal
medicines still require rigorous clinical validation and pharmacological
studies. On their own, herbal medicines have slim hope of entering the
mainstream of American healthcare. This is because herbal medicines, in
their traditional forms, suffer a myriad of deficiencies, including heavy
reliance on anecdotal data, a lack of randomized controlled clinical data to
substantiate the therapeutic claims, overly broad and often vague
therapeutic claims, a lack of quality assurance and an unfounded panacea
59. See Joseph Chang, supra note 22, at 214.
60. Id.
61. Pharmanex, 221 F.3d at 1153.
62. Id.
63. Id.
64. See generally DRUG DISCOVERY AND TRADITIONAL CHINESE MEDICINE
(2001).
65. Id.
66. See Joseph Chang, supra note 22, at 216.
Botanical Drugs
"cure all" belief.67 If not dealt with properly, these deficiencies will
continue to undermine the legitimacy of herbal medicines. Subjecting
herbal medicines to standardized manufacturing practice and well-
controlled clinical trials will help overcome these deficiencies. Developing
a drug model for herbal medicines is essential in establishing the true
value and credibility of herbal medicines in the eyes of American
consumers. In sum, the tradition-based herbal medicines and the science-
based western drug development regime have something to offer each
other. The concept of botanical drugs has the potential to embody these
mutual benefits.
However, it would be simplistic and presumptuous to view botanical
drugs as the answer to all problems. In fact, there are many challenges for
developing botanical drugs. For example, technical issues are abundant in
developing herbal extracts with batch-to-batch quality consistency. 6  As
the endeavor is largely unprecedented, there is no ready protocol to
follow. Consequently, companies will need to resolve these technical
issues as they go along, presenting a risky business model from the
perspective of venture capitalist investors.
Furthermore, while botanical drugs promise to lower the cost of drug
R&D, the cost may still remain prohibitive for most industry players,
except the big pharmaceutical powerhouses. To make matters worse, the
initial stage of botanical drug development necessarily entails
experimentation with new protocols and standardization issues, posing a
high cost that might prevent new entrants from competing in the field.
Taken together, the idea of botanical drugs promises to capture the best
of both tradition-based herbal medicine and western drugs. But bringing
this idea from theory to practice will not be automatic or effortless. Thus,
there is a need for an adequate regulatory climate to spur industry efforts
in this direction. This results in several questions. Is the current
regulatory structure adequate to accomplish this goal? Are there any
industrial research and development efforts in this direction? What can be
done to promote industrial efforts in the United States?
67. See Michael Chang, supra note 9, at 171.
68. See Joseph Chang, supra note 22, at 213.
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IV. CURRENT REGULATORY CLIMATE AND ITS RAM[FICATIONS
A. DSHEA and its Impact
In 1994, in response to intense political pressure, Congress enacted the
Dietary Supplement Health and Education Act (DSHEA). 9  Under
DSHEA, medicinal herbs can be marketed as dietary supplements without
prior FDA approval.70 The supplements may carry "structure/function"
claims, claims that a product affects the structure or functioning of the
body, but not claims that they treat, diagnose, cure or prevent disease."
By offering low market entry cost, DSHEA succeeded in making herbal
medicines widely available.72 But the low market entry cost turned out to
be a double-edged sword. By setting a lower regulatory standard,
DSHEA failed to remedy the fallacies associated with the herbal
medicines enumerated in the last section. Four reasons underlie the
failures of DSHEA to make safe and high quality herbal medicines
available to consumers who need them.
First, the lack of a FDA approval requirement for marketing a dietary
supplement provides no incentive for dietary supplement manufacturers to
conduct any substantive research and development. In fact, an "anything
goes" mentality pervades this new industry. Manufacturers are largely
free to experiment with traditional herbs. They often combine traditional
herbs "with other herbs to make new, non-traditional products, use non-
traditional but more cost-effective preparation techniques, promote
traditional herbs for non-traditional purposes, and put them in a more
consumer-friendly yet non-traditional form. This experimentation
eliminates whatever safeguards and level of effectiveness traditional use
offers., 73 Additionally, tremendous price pressure creates a "race to the
bottom" phenomenon in terms of the quality of dietary supplements in the
market.74
69. Pub. L. No. 103-417, 108 Stat. 4325-4335 (1994).
70. Id.
71. Id.
72. See Henry I. Miller and David Longtin, Death by Dietary Supplement,
available at http://www.policyreview.org/augO0/miller.html (last visited Feb. 8,
2003).
73. Cary Elizabeth Zuk, Herbal Remedies Are Not Dietary Supplements: A
Proposal for Regulatory Reform, 11 HASTINGS WOMEN'S L. J. 29, 43 (Winter 2000)
(references therein).
74. See Miller and Longtin, supra note 72 (describing many instances of dietary
supplements with poor qualities).
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As a result, consumers come to associate questionable effectiveness and
harmful side effects with dietary supplements. In turn, this reinforces the
old distrust of traditional herbal medicine, and undermines consumer
confidence in its proliferation. The recent downturn in the market for
dietary supplements seems to obviate this concern.
Second, unsupervised herbal use can potentially pose health and safety
concerns. Many people now use traditional medicine without informing
their physicians, falsely believing that herbal medicines, unlike western
synthetic medicines, have no side effects and no harmful interaction with
prescription or over the counter (OTC) drugs.75
Third, the requirement that dietary supplements are not permitted to
make disease claims prevents the dissemination of potentially useful
information. Ironically, as long as they do not claim the ability to treat
diseases, manufacturers are allowed to make unsubstantiated claims on
their products, fueling further safety concerns.
Fourth, the FDA has not enforced DSHEA. It has implemented
neither the safety requirements, nor the labeling restrictions.76  Some
believe the FDA is purposely undermining the Act, while others say that
this is the result of inadequate FDA resources." The lack of DSHEA
enforcement is further amplified by its disincentivizing effect on
companies who engage in serious research and development efforts to
explore the value of traditional medicines. For example, consider a firm
producing herbal medicines. To market in the United States, it is faced
with two options. It can market them as dietary supplements. Given the
de minims regulation in this area, this option appears attractive.
Alternatively, if the firm wants to get the imprimatur of FDA for its
product, its only option is to develop a new single-chemical-entity drug
from an herb and complete the costly drug approval process. To date,
FDA has never approved a single drug in extract form from a natural
resource. Given the two options, it makes more sense for businesses to
take the dietary supplement route. The dietary supplement's entry cost is
low, and it promises a quick return. The drug route pales in comparison
because it requires a large up-front investment, while the chance for return
remains highly uncertain.78
The potential return for conventional NCE drugs developed from herbs
is directly threatened by dietary supplement free riders. As mentioned
75. See Joseph Chang, supra note 22, at 211.
76. Id., See Also Zuk, supra note 73, at 41-42, 46-47 (references therein).
77. See Miller and Longtin, supra note 72, at 2.
7& See Ward, supra note 26, at 1-2.
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above, notwithstanding the potential cost-cutting benefit herbal medicines
may provide, a drug company still needs to invest a substantial amount of
money to develop an FDA-approved drug made from herbs. After FDA
approves an NDA and the drug is marketed, a drug company may find
itself directly competing with a dietary supplement containing the same
active ingredient. Given the low entry cost of the dietary supplement
industry and the abundance of dietary supplement companies already in
the United States, this scenario will not be an infrequent event. Spared of
R&D expenses, these free riders will be able to sell their products at a
significantly lower price. Compounded with pressures from managed care
providers to cut drug costs, patients are more likely to purchase the cheap
substitutes, especially given the added lure of a "natural product."
This nightmarish scenario for pharmaceutical companies has recently
been mitigated by the Pharmanex decision.7 9 In that case, the 10th Circuit
recognized the disincentive effect of the DSHEA for drug development.'
The Pharmanex decision stands for the proposition that a company will be
barred from marketing a dietary supplement containing a natural
substance that is the active ingredient in a previously approved drug
product."1  Under DSHEA, the definition of "dietary supplement"
excludes both "an article that is approved as a new drug," and "an article
authorized for investigation as a new drug...for which substantial
investigation ha[s] been instituted and for which the existence of such
investigations has been made public." ' The Pharmanex opinion construed
the word "article" broadly to include active ingredients as well as the final
drug product. 8  This construction is likely applicable to the second
exclusion, where an investigation has been initiated for a new drug. Thus,
under Pharmanex and DSHEA, the bar reaches any company that
markets the same natural substance as a dietary supplement prior to
investigation and approval of the new drug.
To make matters worse, drug products developed from botanical
products are often unable to obtain a composition patent due to the fact
that these products are naturally occurring.' They have to settle for use
patents, which are much harder to defend and are less valuable. As a
79. Pharmanex, 221 F.3d at 1151.
80. Id. at 1159.
81. Id. at 1158.
82. Pub. L. No. 103-417, 108 Stat. 4325-4335, Sec. 3(a)(ff)(3)(B) (1994).
83. Pharmanex, 221 F.3d at 1154-1156.
84. See 35 USC §101 (2000) (proper subject matter of patents) and Funk Bros.
Seed Co. v. Kalo Inoculant Co., 333 U.S. 127 (1948).
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result, companies that engage in the risky enterprise of developing drugs
from traditional herbs see a serious prospect of getting whipsawed. The
chance of recovering the investment is slim and the chance of making a
profit is even less probable.
In short, rather than promoting the mainstreaming of traditional
medicines, the advent of dietary supplements, in practice, has the opposite
effect. The current bifurcation along the line of dietary supplement and
drug runs the danger of foreclosing pharmaceutical industry efforts in the
United States to develop traditional medicinal herbs into drug products.
B. Danger: American Companies Losing Competitive Advantages in
Developing Botanical Drugs?
Given the unfavorable regulatory climate, it is no surprise that there are
only a small handful of American companies that develop botanical drugs
through the conventional IND/NDA route.
Six American companies claim to be in the business of developing
botanical drugs, including Ancile Pharmaceuticals, Pharmanex,
Phytomedics, Pharmaprint Botanical Pharmaceuticals, Andes
Pharmaceuticals and Phytoceutica.u As an indication of the lack of
serious industrial efforts in this area, all six companies are small start-up
ventures. For example, Ancile Pharmaceuticals, based in California,
employs thirty professionals.' Similarly, Phytomedics, Inc., a New Jersey-
based company, has a small R&D staff of twenty scientists.8 ' Among these
companies, only Ancile and Phytomedics have progressed to the clinical
trial stage.- As of April 2001, Ancile has three effective IND applications
filed with the FDA. In December 2000, Ancile successfully completed a
double blind, placebo-controlled Phase II trial for ANPH 101, a drug
product intended for sleep disorders.' Phytoceuticals, based in New
Haven, Connecticut, cleared an IND application for one of its
85. See infra notes 86-107 and accompanying text.
86. See Ancile Company Profile, at http://www.ancile.com/company2.html (last
visited Jan. 30, 2003).
87. See Phytomedics Company History, at http://www.phytomedics.com/
company.htm (last visited Jan. 30, 2003).
88 Id., See Also Ancile Company Profile, at http://www.ancile.com/
company2.html (last visited Jan. 30, 2003).
89. See Ancile Company Profile, supra note 86.
90. Id.
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chemotherapy modulating drug products in August 2001. 9' Phase I and II
clinical trials are currently under way.92 Others, like Phytomedics, are still
in the early stage of drug development called lead identification. 93 For
Pharmanex and PharmaPrint Botanical Pharmaceuticals, botanical drug
development through the IND/NDA route remains no more than a grand
vision. Instead, the primary business of these two companies is currently
dedicated to marketing dietary supplements.94
Ostensibly missing from the scene are the major pharmaceutical
powerhouses, with Pfizer as the only exception. In the absence of major
pharmaceutical players, large-scale investment in this area seems unlikely.
On the other hand, foreign firms are eager for a slice of the American
botanical drug market. In fact, foreign firms already have a head start. For
example, Phytopharm, a British botanical pharmaceutical company, has
been in the business of botanical drug development for over eleven years.'
In September 2000, Phytopharm announced that it had initiated a Phase I
clinical evaluation for another botanical product, P58.96 According to the
company news release, "P58 is one of a family of phytochemicals isolated
from traditional treatments for the elderly that have previously been
shown to offer significant benefit in the treatment of senile dementia." 97
Similarly, another British pharmaceutical company, Oxford Natural
Products, is dedicated to the "development of novel pharmaceuticals and
nutraceuticals from plants., 98 As of 2001, the company entered three
products into clinical evaluations." Among them, ONP-17, which treats
hepatitis-C symptoms, is composed of extracts of traditional Chinese and
91. See Phytoceuticals, Inc., Products Under Development, at
http://www.phytoceutica.com/products.htm (last visited Jan. 30, 2003).
92- Id.
93. See Phytomedics Company History, supra note 87.
94. See Pharmanex: Our Company, at http://www.pharmanex.com/
ourcompany.shtml (last visited Jan. 30, 2003). (Pharmaprint's website says nothing
about production.)
95. See Phytopharm: History, at http://www.phytopharm.com/corpinfo/
history.shtml (last visited Jan. 30, 2003).
96. See Press Release, Phytopharm, Phytopharm Commences Phase I clinical
trials in Alzheimer's disease and related dimentias (Sept. 11, 2000), available at
www.phytopharm.com/news/pressreleases2000/press043-20000091 1.shtml.
97. Id.
9& See Oxford Natural Products: Company Profile, at
http://www.oxfordnaturalproducts.com/site/onp/profile (last visited Jan. 30, 2003).
99. Id.
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Western herbs. 00  Chronic hepatitis-C inflicts over 300 million patients
worldwide.0 ' Not shy about its intention to enter the American market,
Oxford Natural Products explicitly points out on its website that "in
America, [hepatitis-C] is four times more prevalent than AIDS.',
10 2
The threat of competition for the American botanical drug market is
not limited to European nations. CV Technologies, Inc. (CVT), a
Canadian herbal drug developer, has been engaged in the business of
developing nutraceuticals for over ten years.13 In October 1999, CVT
obtained its first IND clearance with FDA for its nutraceutical product,
CVT-E002."' CVT-E002 is a "multicomponent phytopharmaceutical
extracted from North American ginseng... intended for use as a
preventative against acute respiratory infection."'0 5 In September 2000,
CVT announced the successful completion of its first Phase II clinical trial
of CVT-E002, and is ready to proceed with a second, much larger Phase II
clinical trial.00 These trials are double blind and placebo-controlled. 7
The unusual dominance of foreign entities among the critics of FDA's
new Draft Guidance gives another glimpse of the eagerness of foreign
firms to join the American botanical drug market. Of the eighteen firms
who filed comments to date, only four are American drug companies,
while nine are foreign industrial entities representing either individual
companies or associations of companies. According to Dr.Yuan-yuan
Chiu, Director of Office of New Chemistry for Drug Evaluation and
Research at the FDA, the disparity in responses is possibly indicative of a
disparity between the United States and other nations in the level of
activities within the botanical drug field.'0
100. See http://www.oxfordnaturalproducts.com/site/onp/17 (last visited Feb. 8,
2003).
101. Id.
102- See ONP-17: Hepatitis C, at http://www.oxfordnaturalproducts.com/
site/onp/17 (last visited Jan. 30, 2003).
103. See CV Technologies, Inc.: Clinical Trials, at
http://www.cvtechnologies.com/s/ClinicalTrials.asp (last visited Jan. 30, 2003).
104. Id.
105. Id.
106. Id.
107. Id.
108. Telephone Interview with Dr. Yuan-yuan Chiu, Director, Office of New
Chemistry for Drug Evaluation and Research, Food and Drug Administration
(March 11, 2002).
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Table 1. Distribution of commentators on the Draft Guidance' 9
Origination Drug Companies Others
(consulting,
governmental
agency, trade
association)
United States 4 3
Europe 4 0
Asia 2 1
Canada 3 0
Global 1 (Pfizer) 0
Total 14 4
If left unchanged, the lack of industrial efforts in the United States can
potentially cost America its competitive advantage in the global market.
The American drug industry is not the only one suffering from the current
regulatory regime. As pharmaceutical companies shy away from making
effective drugs from herbal medicines, consumers will be deprived of these
potentially beneficial medicines. The massive under-regulation of dietary
supplements hardly relieves this deprivation, as the market is now flooded
with many dietary supplements of dubious quality.' This unsatisfactory
state of affairs calls for changes in regulatory policy.
C. The Case for Lowering Approval Standards for Botanical Drugs
It is time for FDA to get involved. Americans have grown to trust FDA
as the gatekeeper of new drugs, and consequently, a stamp of approval on
herbal medicines from FDA will pave the way for their mainstream
acceptance by many Americans.
However, a viable alternative is for FDA to alter the current all-or-
nothing regulatory state of affairs, which is comprised of stringent armed-
to-the-teeth regulation for new drugs approval on one end, and a complete
lack of scrutiny for the marketing of dietary supplements on the other. A
balance can, and should, be struck. FDA can create a new category for
botanical drugs by placing herbal medicines into the FDA approval
process, but with the application of substantially lower approval standards.
109. Based on a search of the FDA website (http://www.fda.gov) using the term:
comment and "botanical products".
110. See Miller and Longtin, supra note 72.
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Adopting standards substantially lower than those required for
conventional drugs is justified by the fact that many herbal medicines
already have extensive prior marketing experience before FDA
applications are filed."' TCM is an example. Four thousand years of trial-
and-error medical practice and documentation have reasonably
established their safety and effectiveness. Furthermore, their continued
marketing in China and other Asian and European nations provides
evidence of their safety.
In fact, many other industrial nations have already adopted a similar
practice. For example, France permitted the registration of "vegetable
drugs" under "an abridged dossier" in 1990.112 Moreover, the safety of
herbal remedies, including "historical proof of their widespread traditional
use and their well established use in self-medication," was taken into
account. "3  Likewise, in Germany, "bibliographic data on the well
established use of herbal medicines are accepted" by the Federal Institute
for Drugs and Medical Devices (the German equivalent of the FDA) for
determining safety and efficacy of drug products."4
Nevertheless, some might raise the objection that FDA drug approval
standards should not be tampered with to accommodate a new category of
drugs. This objection is misplaced however, for the conventional drug
approval standard for NCE drugs is not set in stone. In fact, the FDA has
frequently invoked criticism for its stringent approval standard and several
reforms have been proposed."5 Critics view the approval standard as
excessive and unnecessary, and have accused it of "[becoming] more
stringent than is socially optimal.""116 In fact, studies have found that more
stringent drug regulations, spurred by the thalidomide tragedy,"7 have
111. Indeed, FDA has acknowledged the value of prior marketing experience in
the Botanical Drug Guidance, See BOTANICAL DRUG GUIDANCE, supra note 9, at
4.
112. See TRADITIONAL MEDICINE PROGRAMME, WORLD HEALTH
ORGANIZATION, REGULATORY SITUATION OF HERBAL MEDICINES: A
WORLDWIDE SURVEY (1998), at 14. [hereinafter WHO SURVEY].
113. Id.
114. Id. at 16.
115. See Ward, supra note 26, at 3.
116. Id. at 1.
117. In the early 1960s, many European women who had taken thalidomide, a
drug to reduce morning sickness, during pregnancy, gave birth to severely
deformed babies. Reports of these incidents prompted the passing of legislation
that increased the FDA's authority over the safety and effectiveness of drugs. See
HUTr & MERRILL, supra note 12, at 452.
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increased the drug development costs by about six percent per annum in
the United States.'1 8 Consequently, these regulations have cut the number
of new drugs introduced in the United States by half relative to other
industrialized nations. 9 The FDA is blamed for maintaining a higher than
optimal drug approval standard out of fear of political pressures.
Approving a non-beneficial and harmful drug leads to more political
backlash for FDA than failing to approve, or simply delaying the approval
of, a beneficial drug. One critic commented that, "no official wants to be
known as the one who approved another thalidomide.""'' The result is a
net social loss due to the failure to approve a truly beneficial drug.
Indeed, "the cost in increased mortality and morbidity was valued at $330
million in [a] 1973 [study]. 122
While no one anticipates a quick turnaround by FDA in its
conventional drug approval standard, adopting a lower standard for a new
category of drugs would require less administrative overhaul and would
be, perhaps, more likely to succeed.
Nevertheless, some may raise health and safety concerns as a result of
reduced FDA scrutiny. While this concern is legitimate, the reality is that
the advent of dietary supplements has already become a threat to public
health and safety. In fact, having FDA become involved in standard
setting will make botanical drugs safer than their dietary supplement
cousins. Because physicians will be involved throughout the prescription
process, a learned intermediary will be able to inform and educate
patients. In contrast to the scarce information provided with the garden-
variety dietary supplement, botanical drugs, like other prescription drugs,
will come with patient package inserts that will supply extensive
information to patients.
A second, and related, concern is that granting FDA approval of
botanical drugs under a reduced standard may undermine the credibility
of FDA, and consequently all FDA-approved drugs. This paranoia is
premised on an unfounded assumption that botanical drugs will cause
more health and safety problems than conventional single entity drugs.
As mentioned above, extensive clinical data from a wealth of practice and
foreign marketing experience indicates that botanical drugs will at least be
as safe as, if not safer than, their synthetic single-chemical-entity
11& See Ward, supra note 26, at 2.
119. Id.
120. Id. at 3.
121. Id.
122- Id.
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counterparts. Therefore, while there are potential pitfalls, they are
outweighed by the benefits of permitting new botanical drugs.
By embracing herbal remedies, FDA will not be stepping out of its
usual conservative character and taking on a revolutionary role. Rather, it
will be keeping pace with a movement that has already been embraced by
many different sectors of American society. The following tale of
changing names highlights a gradual acceptance of the once deemed
unconventional. "In the 1950's: the American Cancer Society had a
committee on Quackery."' 3 Later, the term quackery was replaced by
"questionable methods," followed by "unproven methods of cancer
management.' 2' Today the same committee is named the "Committee on
Complementary and Alternative Medicine (CAM)."" This image of
keeping up, rather than starting a revolution fits more comfortably with
the conservative temperament of FDA. Conversely, inaction will make
FDA appear unreasonably stubborn in the face of the sea of change
occurring in American society and worldwide, thereby undermining its
credibility in the eyes of consumers.
In summary, giving herbal medicines a green light under a new standard
that takes into account both clinical and prior market experience is
optimal for social and economic benefits. The United States is already
behind in the game of herbal medicines. For American pharmaceutical
companies to stay competitive in the global drug market, a receptive
regulatory environment is urgently needed.
V. FDA DRAFT GUIDANCE
The FDA Draft Guidance for Industry on Botanical Drug Products,
released in August 2000 for public comment, signals a meaningful first step
toward a favorable regulatory climate for companies to engage in
substantial R&D efforts with herbal medicines.'26 In this document, FDA
proposed to approve botanical drugs, in extract forms, as a new class of
drugs for the first time.
The Draft Guidance is significant for two reasons. First, it has the
potential, if enforced appropriately, to eliminate non-conforming
standards and bring uniformity to the use of herbal medicine, which is now
largely dominated by the chaos of dietary supplements. It will promote
123. See Craig Lambert, The New Ancient Trend in Medicine, HARVARD
MAGAZINE (March-April 2002), at 46.
124. Id.
125. Id.
126. See BOTANICAL DRAFT GUIDANCE, supra note 10.
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the safety, quality and efficacy of herbal medicine usage. Second, with the
blessing of FDA, herbal medicines, in their reincarnation as botanical
drugs, will finally have a real hope of entering mainstream healthcare in
the United States.
In summary, the Draft Guidance explains when a botanical drug may be
marketed under an OTC drug monograph and when FDA approval of a
new drug application is required for marketing. 7  It also provides
guidance to sponsors on submitting investigational new drug applications
(INDs) for botanical drug products.'9 Recognizing the complexity of
botanicals, the Draft Guidance deems it appropriate to adopt regulatory
policies that differ from those for synthetic, semisynthetic, or otherwise
highly purified drugs.2 9  In certain circumstances, prior domestic
marketing data are proposed to substitute, either partially or completely,
for the pre-clinical data to support an IND for initial clinical studies.'
The next section will focus on the coverage of the Draft Guidance and
new approval standard for botanical drugs. The analysis will take into
account relevant public comments submitted to FDA to date.
A. Scope of Botanical Drugs
The Draft Guidance delineates the scope of botanical drugs quite
narrowly. The basic definition of botanical drugs in the Draft Guidance is
in line with the basic approach of the Federal Food, Drug, and Cosmetic
Act (FDCA), which distinguishes between a food and a drug on the basis
of intended use.13' The Draft Guidance defines botanical drugs as "[a]
botanical product that is intended for use as a drug; a drug product that is
prepared from a botanical drug substance."'32 From this basic definition,
the Draft Guidance explicitly excludes "highly purified or chemically
modified substances derived from natural sources" from the reach of
127. Id. at 1.
128. Id.
129. Id.
130. Id. at 6.
131. Under FDCA, "food" is defined as including "articles used for food or
drink for man", "drugs" are defined as including "articles intended for use in the
diagnosis, cure, mitigation, treatment, or prevention of disease in man", and
"articles intended to affect the structure or any function of the body of man." See
21 U.S.C. § 321(f)(1)(2000) and 21 U.S.C. at § 321(g)(1)(B).
132. See BOTANICAL DRUG GUIDANCE, supra note 10, at 36.
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botanical drugs.'33 As a justification for this exclusion, the Draft Guidance
explained that once purified, these substances "can readily be fully
characterized."'T 34
At first blush, this narrow definition appears to indicate FDA's
reluctance to fully embrace herbal medicines, as it stops short of
encouraging full-fledged conventional drug development that builds on
herbal medicine knowledge. But there may be other justifications for this
approach. For example, the narrow definition may well indicate that FDA
has accepted the conventional wisdom of herbal medicine practitioners,
that the whole is greater than the sum of its parts. Under the idea of
synergism, multiple components in many herbal extracts may work
together to alleviate disease. Developing a single-chemical-entity drug
from herbal medicine appears to be unadvantageous, not to mention the
potential side effects resulting from the purified chemicals.
Furthermore, the FDA may need to retain a uniform approval standard
for NCE drugs. The FDA should not discriminate among NCE drugs
developed with different methodologies; for example, recombinant
biotech drugs that are drugs developed using genomic knowledge as
opposed to drugs purified from herbal medicines. Given the current
complex technology involved in drug development, choosing
methodologies is beyond the expertise of a federal bureaucracy like FDA.
Thus, it is wise for FDA not to play favoritism among NCE drugs.
It is interesting to note that some industrial nations have adopted
broader conceptions of botanical drugs. In France, herbal medicines are
simply defined as medicines that have "exclusively plants or plant extracts"
as active ingredients.' Similarly, in Greece, a regulation for herbal
medicines, published in 1994 by the Ministry of Health, defined herbal
medicines as "medicines which contain as active ingredients only plants or
preparations of plants.', 3 6 These broader definitions would cover NCE
drugs developed from plants. It should be noted, however, that regulations
for NCE drugs in these nations are much less stringent than those in the
United States. Thus, granting herbal medicine status to NCE drugs derived
from botanicals would not amount to a big compromise in the approval
standards in France and Greece. In fact, the narrow conception of botanical
133. This is indicated twice in the Draft Guidance, once in the definition of
"botanical drug substance," and again in the background section of the text. Id. at
2,36.
134. Id. at 2.
135. See WHO SURVEY, supra note 112, at 14.
136. Id. at 16.
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drugs in the Draft Guidance could simply be a function of the highly
stringent regulation for conventional drugs imposed by the FDA in the
United States. Absent a drastic reform to lower the NCE drug approval
standard, bringing NCE drugs that are developed from botanicals into the
botanical drug category may be too drastic a measure for the FDA.
Makers of new NCE drugs purified from medicinal herbs are thus
directly barred from benefiting under the relaxed approval standard. It is
unclear, however, what comes within the ambit of "highly purified" and
therefore gets excluded from the scope of botanical drugs. The definition
section gives no definition to the term "highly purified".13 As noted by
the comment from Tibotec Pharmaceuticals Ltd., a Belgium-based
pharmaceutical company, the preparation of many herbal extracts entails
multiple steps of purification.1 38 Would the herbal extracts prepared this
way satisfy the "highly purified" standard in the Draft Guidance and thus
not be a botanical drug for the purpose of the Draft Guidance? Such a
construction is unlikely, as it directly conflicts with the basic premise of the
Draft Guidance, which is to grant new drug status to botanical extracts.
The final Guidance should clarify that the term "highly purified" is limited
to drugs with single active chemical ingredient purified from botanicals.
B. Regulatory Carrots: Games of Gives and Takes
The Draft Guidance grants three main benefits for botanical drug
developers. In general, the NDA route for botanical drugs espoused by
the Draft Guidance parallels closely the route for an NCE drug.
The foremost benefit is the recognition of prior human use as
supporting data in the initial stages of clinical trials. In the case of
botanical products legally marketed in the United States with no known
safety issues, the chemistry, manufacturing and controls (CMC) and
animal toxicology data may be "markedly reduced" for initial clinical
studies.'39 Indeed, the Draft Guidance points out that "in most cases,
additional toxicology and CMC data will not be required.' ' 40 But, not all
prior human use data are treated equally. Positive foreign marketing
experience is deemed less valuable than marketing experience in the
137. BOTANICAL DRUG GUIDANCE, supra note 10, at 36-38.
138. Letter from Fiona McAndrew, Regulatory Affairs Officer, Tibotec
Pharmaceuticals Ltd., to the Food and Drug Administration, Dockets
Management Branch 2 (Dec. 8, 2000), available at http://www.fda.gov/
ohrms/docketsdailys/00/DecOO/122100/cOO0024.pdf.
139. BOTANICAL DRUG GUIDANCE, supra note 10, at 4.
140. Id.
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United States. Botanical products previously marketed exclusively in
foreign markets must supply more information to initiate clinical Phase I
and II trials. ' Decisions as to the nature of information needed for these
products will be determined on a case-by-case basis.' 2 At the other end of
the spectrum, those botanical products that have not been legally
marketed anywhere, or have known safety issues are subject to the same
standard as their NCE counterparts.
This benefit, however, stops at Phase III. Here, the Draft Guidance
turns a sudden blind eye to the fact that high quality human safety data are
available for many botanical products. Botanical drugs are held to the
same high standard as a NCE drug for the purpose of Phase III clinical
trials.' 43  Manufacturers will have to supply full, non-clinical toxicology
program, full clinical program and equivalent CMC data.'" As one
commentator pointed out, the reservation here highlights the general
difficulty to alter "institutional thinking" at FDA.4 The reservation here
gives the Draft Guidance a schizophrenic character and seriously
undermines the benefits granted to botanical drugs. The next section will
discuss more about its effect on incentives for botanical drug makers.
The Draft Guidance indicates that applicants for a botanical drug may
not need to identify its active constituents during the IND stage or in an
NDA submission if identification "is shown to be infeasible".' 6 More
importantly, the Draft Guidance acknowledges broadly that, in many
cases of botanical drugs, neither the active ingredient nor its biological
activity is well characterized. 14 This acknowledgement is likely to figure
into the case-by-case approval review process and tip the scale further to
favor approving botanical drugs under a less stringent standard.
The problem with this regulatory carrot, however, is that it is tethered
to an ambiguous "infeasible" standard. Several comments raised this
objection. The Consumer Healthcare Products Association suggested
that FDA not "leave open-ended statements" that can lead to inconsistent
141. See id. at 6-7 and 12-16.
142. See id. at 15.
143. See Draft Guidance, supra note 10, Section IX, at 24-35.
144. Id.
145. Floyd E. Leaders, Jr., FDA Guidance for Botanical Drug Products: Review
and Commentary, AHPA REPORT (Fall 2000), available at http://www.ahpa.org/
fall2000.pdf.
146. BOTANICAL DRUG GUIDANCE, supra note 10, at 4.
147. Id.
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interpretations."' Phytopharm, an UK-based pharmaceutical company
requested that the final Guidance clarify the issue by including examples
of botanical drugs that satisfy the burden of demonstrating infeasiblity' 49
Finally, a less articulated but nonetheless valuable benefit is the
exemption from the combination drug regulations.50  By definition,
botanical drugs are combinations of multiple components, and sometimes,
multiple active ingredients.' Under the FDA combination drug
regulation, the maker of a fixed-combination drug would have to
demonstrate that each component or active ingredient contributes to the
claimed therapeutic effects.'52 Imposing such a requirement on botanical
drugs would mean practical death for these drugs. Thus, an exemption
from the requirement is valuable.
The exemption is limited, however, to botanical drug products that are
derived from a single part of a plant, such as leaves, stems, roots or seeds,
or from an alga or macroscopic fungus. 53  Botanical drug products
composed of multiple parts of a single plant, or of parts from different
plants, are not within the exemption. Thus, these drugs will still have to
comply with the combination drug requirement. FDA, however, does not
completely shut the door. A ray of hope remains as FDA indicated its
intention to exempt this group of botanical drugs from the combination
drug requirement "under certain circumstances". '
The exemption from the combination drug requirement is consistent
with the general recognition of the difficulty of identifying active
ingredients in the herbs. In addition, the exemption is also in line with a
more fundamental recognition that herbal medicines work in ways
different from that of conventional NCE drugs. Synergism among
148. Letter from R. William Soller Ph.D., Senior V.P. and Director of Science
and Technology, to the Food and Drug Administration, Dockets Management
Branch (Oct. 10, 2000), available at http://www.fda.gov/ohrms/dockets/
dailys/00/OctOO/101700/c000014.pdf (last visited Oct. 13, 2002) [hereinafter CHPA
Comments].
149. Letter from Andrew Whiles, Director of Regulatory Affairs, Phytopharm,
to the Food and Drug Administration, Dockets Management Branch (December
21, 2000), available at http://www.fda.gov/ohrms/dockets/dailys/O0/
DecOO/122600/c000026.pdf.
150. See BOTANICAL DRUG GUIDANCE, supra note 10, at 5.
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multiple components, as mentioned above, underscores the need for
crafting rules different from conventional NCE drugs.
C. Potential Ramification for Makers of Botanical Drugs
1. On the Cost Side
Despite the best intentions, the Draft Guidance delivers limited
incentives for the development of botanical drugs. Lowering the entry
barrier to initial phases of clinical trials for botanical drugs conceivably
reduces the cost of preparing botanical drug candidates for clinical trials.
But the hurdle of the Phase III clinical trials remains formidable. As
Phase III entails the most extensive clinical trials and thus the most
expense, preserving the stringent standard for Phase III clinical trials
means that the bulk of the cost in bringing a drug to market of marketing a
drug will not go away for botanical drugs.
Furthermore, retaining the same requirement for Phase III may impose
more costs on botanical drug makers than on NCE drug makers. As FDA
itself concedes in the Draft Guidance, the nature of botanical products
makes them non-conducive to conventional methods of purification and
characterization.15 In fact, to justify its exclusion of "highly purified"
substances from the scope of botanical drugs, the FDA offers the reason
that "these substances can readily be fully characterized. 56 A negative
corollary of this statement is that botanical drug products are much harder
to "fully characterize" according to the FDA's standard. Yet, the FDA
presses on, and demands essentially the same stringent requirement for
botanical drugs as for NCE drugs in Phase III trials. For prospective
botanical drug developers, a requirement to comply with the arcane
standards of Phase III, which was originally designed for NCE drugs, may
translate into additional costs. Thus, by essentially forcing square pegs
into round holes, the FDA places additional burdens on botanical drug
developers. In a sense, FDA is giving benefits to botanical drug makers
with one hand (concession at Phase I and II), and taking them back with
another (reservation at Phase III). The net result is a de minimis benefit
for botanical drug makers.
To further complicate the picture, the Draft Guidance provides no
simple "cook book for new botanical drug applications.', 5 7 While the
document signals a clear willingness by the FDA to work with drug
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makers to foster the growth of botanical drug development, the guidance
itself is perforated with ambiguities. The use of "may" and "might",
instead of "shall" and "must" is profuse throughout the document.5 8
Similarly, as mentioned above, the use of phrases such as "shown to be
infeasible",59 "when possible"'60 and "under certain circumstances161
leaves many approval standards undesirably open-ended.
To an industry where certainty equals gold, uncertainty undercuts
incentives. As expected, comments from the pharmaceutical industry
vigorously objected to the ambiguities in the document. These comments
uniformly requested the FDA to provide clarification in the final
Guidance. 162 Conceivably, the industry will need to rely on the framework
provided by the final Guidance to shape itself.
This said, it should be recognized that the profuse use of ambiguous
language could simply be an indicia of a new field. At the beginning
stages of any new field, flexible standards, rather than rigid rules are more
workable and conducive to future, as well as, gradual improvement.
Given this consideration, the final Guidance is perhaps unlikely to
incorporate a much clearer standard.
15& See, e.g., BOTANICAL DRUG DRAFr GUIDANCE, supra note 10, at 4, ("active
constituents in a botanical drug might not need to be identified"; and "preclinical
pharmacology and toxicology information that should be provided for legally
available botanical products with no known safety issues during initial clinical trials
may be markedly reduced.").
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122600/c000026.pdf; Letter from R. William Soller, Ph.D., Senior Vice President
and Director of Science and Technology, Consumer Healthcare Products
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101700/c000014.pdf; Letter from Karen K. Church, Vice President, Regulatory
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In this context, it is worth noting that historically, IND and NDA
reviews have been conducted on a case-by-case basis for NCE drugs.' 63 By
the same token, IND and NDA reviews for botanical drugs will likely be
subjected to the same case-by-case review. Thus, the implication for the
industry will become increasingly clear as FDA begins to review and make
decisions whether to approve or disapprove botanical drugs. Currently
there are more than one hundred botanicals either individually or in
formulas currently going through FDA's clinical trials.' 6' To date, no
single NDA has been approved or even reviewed by an advisory
committee, for a botanical drug product .' The methods with which the
FDA carries out the Guidance in the IND/NDA approval process for
these botanical drugs in the next few years will be instrumental in shaping
the direction of the industry.
2. The Return Side
The incentive structure for botanical drugs, provided by the Draft
Guidance, also tracks the structure for other kinds of drugs. In other
words, the Draft Guidance provides that a botanical drug enjoys five-year
marketing exclusivity if it is a new chemical entity, or otherwise a three-
year exclusivity, from the time of approval.' 66 The differential treatment
depends on whether a drug's active constituent is a new chemical entity.'
67
This simple scheme turns out to be anything but simple with botanical
drugs. As acknowledged in the Draft Guidance, in most cases the active
constituent of a botanical drug will be unknown.' 68 Therefore the length of
the marketing exclusivity for these botanical drugs depends on how one
interprets the term "active constituent" in the Draft Guidance. A narrow
construction of "active constituent" means that most applicants for
botanical drugs will not be able to claim the benefit of new chemical entity
and the five-year exclusivity associated with it. As a result, most botanical
drugs with unknown active constituents will enjoy only three-year
marketing exclusivity. On the other hand, a broader construction, as
espoused by the Consumer Healthcare Products Association, suggests that
the entire botanical drug product should be considered the active
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constituent, and thus the "new chemical entity.' ' 69 Under this broad
construction, these botanical drugs will enjoy five-year marketing
exclusivity.
Moreover, the Draft Guidance does nothing to prevent the free rider
problem mentioned in Section IV. The marketing exclusivity only works
against other drug makers, not against dietary supplements manufacturers.
Therefore, this arrangement does not solve the remaining free rider
problem after the limit prescribed by the Pharmanex decision, as
described in Section IV. More specifically, dietary supplement
manufacturers are free to market a dietary supplement with the same or
substantially similar herbal extracts as that in a botanical drug, as long as
they can prove that they marketed their product prior to the initiation of
clinical trials of a botanical drug.70 The advent of Final Guidance means
that botanical drugs will have the blessing of FDA approval and come with
better quality and safety assurance. But they will also come at a
substantially higher price compared to their dietary supplement
counterparts, making botanical drug makers vulnerable to price
undercutting by dietary supplement manufacturers. This free rider
problem threatens the chance for pharmaceutical companies to recoup
their R&D costs, which will be substantial under the Draft Guidance.
Taken together, the Draft Guidance fails to deliver real and substantial
cost-cutting benefit for botanical drug developers. At the same time, it
leaves the return for botanical drugs uncertain.
D. Proposals for Further Rule Changes
While the Draft Guidance is a meaningful step forward, it still imposes
daunting hurdles for botanical drug makers to overcome. To effectively
promote the growth of botanical drug development and to bring beneficial
drugs at a faster rate to patients, the final guidance should consider
making the following changes.
The foremost change should be in the requirement for Phase III clinical
trials. Prior human use data should be taken into account as valid data in
this phase, consistent with the approach taken in the Draft Guidance for
the first two phases. In addition, the FDA should consider the nature of
the botanical products when crafting standards for Phase III. Blind
adherence to the existing standards designed for NCE drugs makes no
analytical sense. To aid its efforts to craft standards that are applicable to
botanical products, the FDA may capitalize on the resources and expertise
169. See CHPA Comments, supra note 148, at 4.
170. See Pharmanex, 221 F.3d at 1158-1159.
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of another federal agency, namely the newly created National Center for
Complementary and Alternative Medicine (NCCAM).
The final guidance should also state clearly that all the special benefits
available to small molecular weight or recombinant drug products are
offered to botanical drug products. For example, if a botanical drug is
intended to be used for a life-threatening disease, all the provisions for
expedited review, treatment INDs and emergency INDs, should apply to
the botanical drug. Similarly, if a botanical drug is intended for use for a
rare disease, it should also be considered under the Orphan Product
Amendments (including Orphan Product Designation, tax advantages,
and seven-year marketing exclusivity).' 7'
CONCLUSION
While herbal medicines are attractive alternatives for new drug
development, it is important to recognize both the advantages and
problems of herbal medicines from both technical and regulatory
perspectives. To this end, special rules for governing the development of
herbal medicines into FDA approved drugs are needed. With such rules
in place, herbal medicines will become a crucial component of our arsenal
against diseases. The FDA Draft Guidance for Botanical Drug Products
represents a positive step toward this direction. However, the Draft
Guidance is still largely based on regulations and policies developed for
traditional new chemical entity drugs. As such, it fails to provide clarity
and adequate incentives clarity for the drug industry to develop botanical
drugs from herbal medicines. These concerns should be addressed in the
FDA Final Guidance for botanical drug products.
171. Id.
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